Table 2.
Correlation between SOX9 RNA expression and clinicopathological parameters of patients with thymomas in the TCGA cohort.
| Clinicopathological parameters | SOX9 | P | |
|---|---|---|---|
| Low (n = 54) | High (n = 54) | ||
| Age (years, mean ± SD) | 54.65 ± 12.78 | 59.89 ± 12.92 | 0.038 |
| Sex | 0.847 | ||
| Male | 29 (49.15%) | 30 (50.85%) | |
| Female | 25 (51.02%) | 24 (48.98%) | |
| Histological type | <0.001 | ||
| A | 1 (6.67%) | 14 (93.33%) | |
| AB | 12 (33.33%) | 24 (66.67%) | |
| B1 | 13 (92.86%) | 1 (7.14%) | |
| B2 | 22 (75.86%) | 7 (24.14%) | |
| B3 | 6 (42.86%) | 8 (57.14%) | |
| History of myasthenia gravis | 0.294 | ||
| No | 34 (47.89%) | 37 (52.11%) | |
| Yes | 20 (58.82%) | 14 (41.18%) | |
| NA | 0 | 3 | |
| Masaoka stage | 0.532 | ||
| I-II | 47 (52.22%) | 43 (47.78%) | |
| III-IV | 7 (43.75%) | 9 (56.25%) | |
| NA | 0 | 2 | |
| Radiation therapy | 0.012 | ||
| No | 29 (40.85%) | 42 (59.15%) | |
| Yes | 24 (66.67%) | 12 (33.33%) | |
| NA | 1 | 0 | |
| New tumor event after initial treatment | 0.221 | ||
| No | 46 (47.92%) | 50 (52.08%) | |
| Yes | 8 (66.67%) | 4 (33.33%) | |
TCGA, The Cancer Genome Atlas; SD, standard deviation; NA, not available.